Ainscough, Benjamin J. http://orcid.org/0000-0001-8340-514X
Barnell, Erica K. http://orcid.org/0000-0003-1631-1201
Ronning, Peter
Campbell, Katie M. http://orcid.org/0000-0001-6491-4432
Wagner, Alex H. http://orcid.org/0000-0002-2502-8961
Fehniger, Todd A. http://orcid.org/0000-0002-8705-2887
Dunn, Gavin P.
Uppaluri, Ravindra
Govindan, Ramaswamy
Rohan, Thomas E.
Griffith, Malachi http://orcid.org/0000-0002-6388-446X
Mardis, Elaine R.
Swamidass, S. Joshua
Griffith, Obi L. http://orcid.org/0000-0002-0843-4271
Article History
Received: 26 March 2018
Accepted: 14 September 2018
First Online: 5 November 2018
Competing interests
: R.G. consults for Eli Lilly and Genentech. R.G. is on the board/honorarium for EMD Serono, Bristol-Myers Squibb, Genentech, Pfizer, Nektar, Merck, Celgene, Adaptimmune, GlaxoSmithKline, Phillips Gilmore. All remaining authors declare no competing interests.